HCW Biologics Inc.
HCWB
$2.46
-$0.05-1.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -97.93% | 24,133.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -97.93% | 24,133.33% | |||
| Cost of Revenue | 1,967.57% | -48.61% | |||
| Gross Profit | -101.44% | 120,861.11% | |||
| SG&A Expenses | 1.61% | -48.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.16% | -33.71% | |||
| Operating Income | -197.86% | 165.21% | |||
| Income Before Tax | -237.25% | 428.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -250.30% | 382.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -250.30% | 382.83% | |||
| EBIT | -197.86% | 165.21% | |||
| EBITDA | -189.98% | 170.30% | |||
| EPS Basic | -627.69% | 135.70% | |||
| Normalized Basic EPS | -202.12% | 145.24% | |||
| EPS Diluted | -627.69% | 135.70% | |||
| Normalized Diluted EPS | -202.12% | 145.24% | |||
| Average Basic Shares Outstanding | 46.85% | 60.34% | |||
| Average Diluted Shares Outstanding | 46.85% | 60.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||